Overview of the Development and Use of Akt Inhibitors in Prostate Cancer - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2021

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer

Guilhem Roubaud
  • Fonction : Auteur
  • PersonId : 975634
Laurent Brureau
  • Fonction : Auteur
  • PersonId : 1110792
Gilles Créhange
  • Fonction : Auteur
  • PersonId : 1110793
Gaëlle Fiard
Gaëlle Fromont
  • Fonction : Auteur
  • PersonId : 1091348
Raphaële Renard-Penna
  • Fonction : Auteur
  • PersonId : 1110794
Paul Sargos
  • Fonction : Auteur
  • PersonId : 1042270
Guillaume Ploussard

Résumé

Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.
Fichier principal
Vignette du fichier
jcm-11-00160.pdf (484.98 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03531239 , version 1 (18-01-2022)

Identifiants

Citer

Anis Gasmi, Guilhem Roubaud, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, et al.. Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. Journal of Clinical Medicine, 2021, 11 (1), pp.160. ⟨10.3390/jcm11010160⟩. ⟨hal-03531239⟩
91 Consultations
117 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More